3-Deoxyglucosone induces insulin resistance by impairing insulin signaling in HepG2 cells

Molecular Medicine Reports

Volumn 13, Issue 5, 2016, Pages 4506-4512

  Liang, Guoqiang ^a   Wang, Fei ^a   Song, Xiudao ^a   Zhang, Lurong ^a   Qian, Zhen ^a   Jiang, Guorong ^a  

^a Suzhou Hospital of Traditional Chinese Medicine   (China)

Author keywords

3 Deoxyglucosone; Diabetes mellitus; Hepatic insulin resistance; Impaired insulin signaling

Indexed keywords

3 DEOXYGLUCOSONE; GLUCOSE TRANSPORTER 2; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; 3-DEOXYGLUCOSONE; DEOXYGLUCOSE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; FEMALE; HEP-G2 CELL LINE; MALE; METABOLISM; MIDDLE AGED; MOUSE;

ANIMALS; CELL SURVIVAL; DEOXYGLUCOSE; FEMALE; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MICE; MIDDLE AGED; SIGNAL TRANSDUCTION;

EID: 84964790920     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5081     Document Type: Article

References (52)

1. Petersen KF and Shulman GI: New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy. Obesity (Silver Spring) 14(Suppl 1):S34-S40, 2006.
2. Gallagher EJ, LeRoith D and Karnieli E: The metabolic syndrome-from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am 37:559-579, 2008.
3. Goldstein BJ: Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90:3G-10G, 2002.
4. Taniguchi CM, Ueki K and Kahn R: Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115:718-727, 2005.
5. Hunter SJ and Garvey WT: Insulin action and insulin resistance: Diseases involving defects in insulin receptors, signal transduction and the glucose transport effector system. Am J Med 105:331-345, 1998.
6. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N and Geerts A: Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol 47:142-156, 2007.
7. Dou L, Zhao T, Wang L, Huang X, Jiao J, Gao D, Zhang H, Shen T, Man Y, Wang S and Li J: MIR-200s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes. J Biol Chem 288:22596-22606, 2013.
8. Sechi LA and Bartoli E: Mechanisms of insulin resistance leading to hypertension: What we can learn from experimental models. J Investig Med 45:238-251, 1997.
9. Shin D B, Hayase F and Kato H: Polymerization of proteins caused by reaction with sugars and the formation of 3-deoxyglucosone under physiological conditions. Agric Biol Chem 52:1451-1458, 1988.
10. Kusunoki H, Miyata S, Ohara T, Liu BF, Uriuhara A, Kojima H, Suzuki K, Miyazaki H, Yamashita Y, Inaba K and Kasuga M: Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 26:1889-1894, 2003.
11. Supplementto American Academy of Dermatology 66th Annual Meeting: Inhibitors of 3-deoxyglucosone (3DG) treat aging and inflamed skin by preventing the form action of AGEs, oxidative stress and free radicals. San Antonio, Texas: J Am Acad Dermatol 231, 2008.
12. Niwa T: 3-Deoxyglucosone: Metabolism, analysis, biological activity and clinical implication. J Chromatogr B Biomed Sci Appl 731:23-36, 1999.
13. Lal S, Kappler F, Walker M, Orchard TJ, Beisswenger PJ, Szwergold BS and Brown TR: Quantitation of 3-deoxyglucosone levels in human plasma. Arch Biochem and Biophys 342:254-260, 1997.
14. Hamada Y, Nakamura J, Fujisawa H, Yago H, Nakashima E, Koh N and Hotta N: Effects of glycemic control on plasma 3-deoxyglucosone levels in NIDDM patients. Diabetes Care 20:1466-1469, 1997.
15. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD and Szwergold BS: alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726-732, 2001.
16. Sakiyama H, Takahashi M, Yamamoto T, Teshima T, Lee SH, Miyamoto Y, Misonou Y and Taniguchi N: The internalization and metabolism of 3-deoxyglucosone in human umbilical vein endothelial cells. J Biochem 139:245-253, 2006.
17. Kiho T, Asahi T, Usui S, Matsunaga T and Ukai S: Effect of 3-deoxyglucosone on the activities of enzymes responsible for glucose metabolism in mouse liver. Biol Pharm Bull 19:1106-1108, 1996.
18. Sassi-Gaha S, Loughlin DT, Kappler F, Schwartz ML, Su B, Tobia AM and Artlett CM: Two dicarbonyl compounds, 3-deoxyglucosone and methylglyoxal, differentially modulate dermal fibroblasts. Matrix Biol 29:127-134, 2010.
19. Dhar A, Desai KM and Wu L: Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats. Br J Pharmacol 159:166-175, 2010.
20. Jia X and Wu L: Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol Cell Biochem 306:133-139, 2007.
21. Dhar A, Dhar I, Jiang B, Desai KM and Wu L: Chronic methylglyoxal infusion by minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 60:899-908, 2011.
22. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J and Van Obberghen E: Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 55:1289-1299, 2006.
23. Fiory F, Lombardi A, Miele C, Giudicelli J, Beguinot F and Van Obberghen E: Methylglyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia 54:2941-2952, 2011.
24. Wang Q, Jiang Gr and Zhang Lr: Effects of 3-deoxyglucosone on blood glucose of normal mice. Chin J Diabetes 18:220-222, 2010.
25. Jiang G, Zhang L, Ji Q, Wang F, Xu H, Huang F and Wang C: Accumulation of plasma 3-deoxyglucosone impaired glucose regulation in Chinese seniors: Implication for senile diabetes? Diabetes Metab Syndr 6:140-145, 2012.
26. Kato H, Van Chuyen N, Shinoda T, Sekiya F and Hayase F: Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta 1035:71-76, 1990.
27. Jiang GL, Zhang LV, Wang F, Xu H and Fei D: Synthesis and structure analysis of the 3-deoxyglucosone (3-DG). J Soochow Univ 27:60-68, 2011.
28. Zhang L, Jiang G, Yao F, He Y, Liang G, Zhang Y, Hu B, Wu Y, Li Y and Liu H: Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One 7:e37865, 2012.
29. Engelbrecht B, Mattern Y, Scheibler S, Tschoepe D, Gawlowski T and Stratmann B: Methylglyoxal impairs GLUT4 trafficking and leads to increased glucose uptake in L6 myoblasts. Horm Metab Res 46:77-84, 2014.
30. Cordero-Herrera I, Martín MÁ, Goya L and Ramos S: Cocoa flavonoids attenuate high glucose-induced insulin signalling blockade and modulate glucose uptake and production in human HepG2 cells. Food Chem Toxicol 64:10-19, 2014.
31. Schinner S, Scherbaum WA, Bornstein SR and Barthel A: Molecular mechanisms of insulin resistance. Diabetic Med 22:674-682, 2005.
32. Mueckler M and Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med 34:121-138, 2013.
33. Hosokawa M and Thorens B: Glucose release from GLUT2-null hepatocytes: Characterization of a major and a minor pathway. Am J Physiol Endocrinol Metab 282:E794-E801, 2002.
34. Levitsky LL, Zheng Q, Mink K and Rhoads DB: GLUT-1 and GLUT-2 mRNA, protein, and glucose transporter activity in cultured fetal and adult hepatocytes. Am J Physiol 267:E88-E94, 1994.
35. Martinez A, Castro A, Dorronsoro I and Alonso M: Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer and inflammation. Med Res Rev 22:373-384, 2002.
36. Medina M and Castro A: Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 11:533-543, 2008.
37. Ban KC, Singh H, Krishnan R and Seow HF: GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 199:201-208, 2003.
38. Ibrahim SH, Akazawa Y, Cazanave SC, Bronk SF, Elmi NA, Werneburg NW, Billadeau DD and Gores GJ: Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol 54:765-772, 2011.
39. Nachar A, Vallerand D, Musallam L, Lavoie L, Badawi A, Arnason J and Haddad PS: The action of antidiabetic plants of the canadian james bay cree traditional pharmacopeia on key enzymes of hepatic glucose homeostasis. Evid Based Complement Alternat Med 2013:189819, 2013.
40. Xu YY, Wu TT, Zhou SH, Bao YY, Wang QW, Fan J and Huang YP: Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: An in vitro study. Int J Clin Exp Pathol 7:3938-3947, 2014.
41. Okado A, Kawasaki Y, Hasuike Y, Takahashi M, Teshima T, Fujii J and Taniguchi N: Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem Biophys Res Commun 225:219-224, 1996.
42. Song Z, Wang H, Zhu L, Han M, Gao Y, Du Y and Wen Y: Curcumin improves high glucose-induced INS-1 cell insulin resistance via activation of insulin signaling. Food Function 6:461-469, 2015.
43. Ruan CT, Lam SH, Chi TC, Lee SS and Su MJ: Borapetoside C from Tinospora crispa improves insulin sensitivity in diabetic mice. Phytomedicine 19:719-724, 2012.
44. Manna P and Jain SK: Decreased hepatic phosphatidylinositol-3, 4, 5-triphosphate (PIP3) levels and impaired glucose homeostasis in type 1 and type 2 diabetic rats. Cell Physiol Biochem 30:1363-1370, 2012.
45. Wang ZB, Zeng HC, Wei HS, Yi GH, Yu J, Wang YT, Zhang YL and Yin WD: NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3β signalling. J Pharm Pharmacol 64:293-301, 2012.
46. Lavoie L, Band CJ, Kong M, Bergeron JJ and Posner BI: Regulation of glycogen synthase in rat hepatocytes. Evidence for multiple signaling pathways. J Biol Chem 274:28279-28285, 1999.
47. Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806, 2001.
48. Kroh LW: Caramelisation in food and beverages. Food Chem 51:373-379, 1994.
49. Hellwig M, Degen J and Henle T: 3-deoxygalactosone, a 'new' 1, 2-dicarbonyl compound in milk products. J Agric Food Chem 58:10752-10760, 2010.
50. Degen J, Hellwig M and Henle T: 1, 2-dicarbonyl compounds in commonly consumed foods. J Agric Food Chem 60:7071-7079, 2012.
51. Brown TR, Su B, Brown KA, Schwartz MA, Tobia AM and Kappler F: Modulation of in vivo 3-deoxyglucosone levels. Biochem Soc Trans 31:1433-1437, 2003.
52. Lal S, Szwergold BS, Taylor AH, Randall WC, Kappler F, Wells-Knecht K, Baynes JW and Brown TR: Metabolism of fructose-3-phosphate in the diabetic rat lens. Arch Biochem Biophys 318:191-199, 1995.